You can buy or sell XRAY and other stocks, options, ETFs, and crypto commission-free!
DENTSPLY SIRONA, Inc. engages in the design, manufacture, sales, and distribution of professional dental products and technologies. It operates through the Technologies and Equipment, and Consumables segments. Read More The Technologies and Equipment segments comprises dental technology, equipment, and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers, and consumable medical device products. The Consumables segment offers preventive, restorative, instruments, endodontic, and orthodontic dental products. The company was founded in 2016 and is headquartered in York, PA.
52 Week High
52 Week Low
Yahoo FinanceMar 21
Top Ranked Momentum Stocks to Buy for March 21st
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st: Bio-Rad Laboratories, Inc. (BIO): This manufacturer of products and solutions for life science research has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days. Bio-Rad Laboratories, Inc. Price and Consensus Bio-Rad Laboratories, Inc. Price and Consensus More Bio-Rad Laboratories, Inc. price-consensus-c...
Yahoo FinanceMar 20
XRAY vs. CNMD: Which Stock Should Value Investors Buy Now?
XRAY vs. CNMD: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Dentsply International (XRAY) or Conmed (CNMD). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies...
Yahoo FinanceMar 18
BofA Expects Dentsply Sirona's Performance To Improve With New Product Ramp, Cost-Cutting
Dentsply Sirona Inc (NASDAQ: XRAY) is in the midst of a major transition. Potential cost savings should support EPS, and the dental equipment supplier could achieve more consistent revenue growth due to new product launches and a slight improvement in the dental market, according to Bank of America Merrill Lynch. The Analyst BofA's Michael Cherny reinstated coverage of Dentsply Sirona with a Buy rating and a $57 price target. The Thesis Dentsply Sirona has made significant changes to its technology por...
Expected May 6, Pre-Market